Jiangsu Recbio Technology Co (FRA:G93) Treasury Stock: €-12.28 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:G93 Jiangsu Recbio Technology Co Ltd FRA:G93
24 GF Score
Price €0.53
! 6 Warning Signs
View Full Analysis

What is Jiangsu Recbio Technology Co Treasury Stock?

Jiangsu Recbio Technology Co FRA:G93 24 Treasury Stock is €-12.28 Mil as of Dec. 2025. GuruFocus rates FRA:G93 with a GF Score™ of 24/100. The stock has 6 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Jiangsu Recbio Technology Co's treasury stock for the quarter that ended in Dec. 2025 was €-12.28 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Jiangsu Recbio Technology Co Treasury Stock Historical Data

* Premium members only.

The historical data trend for Jiangsu Recbio Technology Co's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Recbio Technology Co Treasury Stock Chart

Jiangsu Recbio Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Treasury Stock
Get a 7-Day Free Trial 0.00 0.00 -6.94 -8.96 -12.28

Jiangsu Recbio Technology Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.52 -8.96 -11.42 -12.28 -12.98
FRA:G93
24GF Score
Jiangsu Recbio Technology Co Ltd FRA:G93
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangsu Recbio Technology Co Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of €-12.28 Mil mean?
Jiangsu Recbio Technology Co (FRA:G93) has a Treasury Stock of €-12.28 Mil as of Dec. 2025. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Jiangsu Recbio Technology Co and its competitors.
Is Jiangsu Recbio Technology Co's Treasury Stock too high?
Jiangsu Recbio Technology Co's current Treasury Stock is €-12.28 Mil. Overall, Jiangsu Recbio Technology Co has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Recbio Technology Co's Treasury Stock compare to VRTX and REGN?
Jiangsu Recbio Technology Co's Treasury Stock of €-12.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Jiangsu Recbio Technology Co and its competitors. Jiangsu Recbio Technology Co's current Treasury Stock is €-12.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Recbio Technology Co stock overvalued right now?
Jiangsu Recbio Technology Co (FRA:G93) has a current Treasury Stock of €-12.28 Mil. The current Treasury Stock is €-12.28 Mil. Jiangsu Recbio Technology Co's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Jiangsu Recbio Technology Co (FRA:G93), the current Treasury Stock is €-12.28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jiangsu Recbio Technology Co Business Description

Other Exchanges 02179:Hong Kong
Address No. 888 Yaocheng Avenue, Medical High-tech District, Jiangsu Province, Taizhou, CHN
Jiangsu Recbio Technology Co Ltd is a vaccine company focused on the research, development, and commercialization of vaccines, with a high-value vaccine portfolio driven by in-house technologies. It has built three vaccine technology platforms: novel adjuvants, protein engineering, and immune evaluation. The company's portfolio currently consists of various vaccines, covering diseases such as cervical cancer, herpes zoster, and respiratory syncytial virus. It has two core strategic products, namely REC610, a novel adjuvanted recombinant shingles vaccine, which is currently in the stage of marketing application in China, and REC603, a recombinant HPV 9-valent vaccine under phase three clinical trial.
24GF Score

Get the complete analysis for FRA:G93

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.53
Price